|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date30 Aug 2012 |
A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome
This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.
100 Clinical Results associated with Nycomed Germany Holding GmbH
0 Patents (Medical) associated with Nycomed Germany Holding GmbH
100 Deals associated with Nycomed Germany Holding GmbH
100 Translational Medicine associated with Nycomed Germany Holding GmbH